1
2
3
4
Castelijns, MC, Helmink, MAG, Hageman, SHJ, Asselbergs, FW, de Borst, GJ, Bots, ML, Cramer, MJ, Dorresteijn, JAN, Emmelot-Vonk, MH, Geerlings, MI, de Jong, PA, van der Kaaij, NP, Kappelle, LJ, Lely, AT, van der Meer, MG, Mol, BM, Nathoe, HM, Onland-Moret, NC, van Petersen, RB, Ruigrok, YM, van Smeden, M, Teraa, M, Vandersteen, A, Verhaar, MC, Westerink, J, Visseren, FLJ
2023
2023
5
6
7
8
9
10
de Vries, Folgerdiena M., Denig, Petra, Visser, Sipke T., Hak, Eelko, Postma, Maarten J.
Veröffentlicht in: de Vries , F M , Denig , P , Visser , S T , Hak , E & Postma , M J 2014 , ' Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands ' , Value in Health , vol. 17 , no. 2 , pp. 223-230 . https://doi.org/10.1016/j.jval.2013.12.010;
2014
Veröffentlicht in: de Vries , F M , Denig , P , Visser , S T , Hak , E & Postma , M J 2014 , ' Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands ' , Value in Health , vol. 17 , no. 2 , pp. 223-230 . https://doi.org/10.1016/j.jval.2013.12.010;
2014